Ticker LaunchReverse merger · Completed · KDNY
Chinook Therapeutics U.S. Inc.
Reverse merger with Aduro Biotech, Inc. (ADRO)
Chinook Therapeutics U.S. Inc. merged into Aduro Biotech, Inc. (ADRO), a clinical-stage biopharmaceutical company that restructured, in a reverse merger that takes the private company public. The agreement was signed and the deal closed on the same day, Oct 5, 2020. The combined company trades as Chinook Therapeutics, Inc. (KDNY) on Nasdaq.
Chinook Therapeutics, Inc. is a biotechnology company discovering, developing and commercializing precision medicines for kidney diseases, including atrasentan licensed from AbbVie.
- Status
- Completed
- Private company
- Chinook Therapeutics U.S. Inc.
- Public company
- Aduro Biotech, Inc. (ADRO)
- Public company business before
- clinical-stage biopharmaceutical company that restructured
- Announced
- Signed and closed the same day
- Closed
- Oct 5, 2020
- Combined company
- Chinook Therapeutics, Inc. (KDNY)
- Exchange
- Nasdaq
- Sector
- Biotech & pharma
More on this deal for subscribers
- Concurrent financing and investors
- Analyst notes from the filings
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Closing 8-K Oct 7, 2020
- Closing press release / exhibit
- All filings on EDGAR CIK 1435049
Other completed reverse mergers
- Sigyn Therapeutics, Inc.into Reign Resources Corporation · Oct 19, 2020
- Unique Logistics Holdings, Inc.into Innocap, Inc. · Oct 8, 2020
- Augmedix, Inc.into Malo Holdings Corporation · Oct 5, 2020
- Guskin Gold Corporationinto Inspired Builders, Inc. · Sep 24, 2020
- R3 Score Technologies, Inc.into Global Boatworks Holdings, Inc. · Sep 23, 2020
- Adicet Bio, Inc.into resTORbio, Inc. · Sep 15, 2020